Hematologic Oncology Update – Podcast

Episodes

Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit
28 Jun· Hematologic Oncology Update
Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics:
Introduction (0:00)Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44)Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07)
CME information and select publications
- Listen Listen again Continue Playing...
- Listen later Listen later
Myelofibrosis and Systemic Mastocytosis — Fifth Annual National General Medical Oncology Summit
24 Jun· Hematologic Oncology Update
Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics:
Introduction (0:00)Systemic Mastocytosis — Dr Hunter (9:33)Myelofibrosis — Dr Yacoub (29:40)
CME information and select publications
- Listen Listen again Continue Playing...
- Listen later Listen later
Missing episodes?

Click here to refresh the feed.
Multiple Myeloma — Fifth Annual National General Medical Oncology Summit
18 Jun· Hematologic Oncology Update
Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:
Introduction (0:00)Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)
CME information and select publications
- Listen Listen again Continue Playing...
- Listen later Listen later
Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit
16 Jun· Hematologic Oncology Update
Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:
Introduction (0:00)Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14)
CME information and select publications
- Listen Listen again Continue Playing...
- Listen later Listen later
Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Fifth Annual National General Medical Oncology Summit
15 Jun· Hematologic Oncology Update
Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:
Introduction (0:00)Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12)CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33)Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44)Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34)
CME information and select publications
- Listen Listen again Continue Playing...
- Listen later Listen later
Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
23 May· Hematologic Oncology Update
Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advances in the treatment landscape over the past year.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
20 Apr· Hematologic Oncology Update
Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of menin inhibitors in the management of AML.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
10 Apr· Hematologic Oncology Update
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
1 Apr· Hematologic Oncology Update
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
23 Mar· Hematologic Oncology Update
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review
21 Mar· Hematologic Oncology Update
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah
13 Mar· Hematologic Oncology Update
Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting
11 Mar· Hematologic Oncology Update
Prof Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
9 Mar· Hematologic Oncology Update
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review
4 Mar· Hematologic Oncology Update
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators
18 Feb· Hematologic Oncology Update
Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
$Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review$

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review
13 Feb· Hematologic Oncology Update
Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
Immune Thrombocytopenia — ASH 2025 Review
6 Feb· Hematologic Oncology Update
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
$Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review$

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review
3 Feb· Hematologic Oncology Update
Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review
21 Jan· Hematologic Oncology Update
Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.
CME information and select publications here.
- Listen Listen again Continue Playing...
- Listen later Listen later
Show more

Episodes

Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit

Myelofibrosis and Systemic Mastocytosis — Fifth Annual National General Medical Oncology Summit

Multiple Myeloma — Fifth Annual National General Medical Oncology Summit

Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit

Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Fifth Annual National General Medical Oncology Summit

Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances

Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances

CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson

Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review

CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson

Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review

CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah

Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting

Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review

Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review

Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review

Immune Thrombocytopenia — ASH 2025 Review

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review

Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review